Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results

被引：0
|
作者：
Fang, S. [1 ]
Xu, T. [1 ]
Liu, N. [1 ]
Wang, X. Y. [1 ]
Cheng, W. W. [1 ]
Fang, H. H. [1 ]
机构：
[1] Nanjing Chest Hosp, Affiliated Brain Hosp Nanjing Med Univ, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
aumolertinib; non-small-cell lung cancer; co-mutations;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-25
引用
收藏
页码：S650 / S650
页数：1
相关论文
共 50 条
  • [31] First-line gefitinib for poor PS patients with EGFR mutations
    Kobayashi, K.
    Inoue, A.
    Usui, K.
    Maemondo, M.
    Okinaga, S.
    Mikami, I.
    Ando, M.
    Gemma, A.
    Morita, S.
    Hagiwara, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Continuous CR for EGFR-Mutated NSCLC with Brain Metastasis and Giant Lung Lesion Using Aumolertinib Plus Radiotherapy as First-Line Treatment
    Wu, Q.
    Li, W.
    Wang, J. T.
    Pu, D.
    Li, Y.
    Xu, F.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S664 - S664
  • [33] First-line gefitinib for elderly patients harboring EGFR mutations
    Asami, K.
    Koizumi, T.
    Amejima, S.
    Morikawa, A.
    Morozumi, N.
    Hirai, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients
    Shen, B.
    Pan, B.
    Wu, Y.
    Shi, L.
    Gao, J.
    Du, X.
    Feng, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S317 - S318
  • [35] Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study
    Huang, M. J.
    Yu, M.
    Gong, Y. L.
    Li, Y. Y.
    Liu, Y. M.
    Peng, F.
    Yu, Y.
    Xiu, W. G.
    Wang, Y. S.
    Zou, B. W.
    Fan, H.
    Zhong, L. Q.
    Liu, T. Q.
    Wang, X. F.
    Xu, Y.
    Zhou, L.
    Lu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S146 - S146
  • [36] Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): A randomized multicenter study
    Hu, Y.
    Zhang, F.
    Zhao, M.
    Zheng, Z.
    Zhang, H.
    Jiang, T.
    Liu, Z.
    Wen, J.
    Gan, X.
    Wang, H.
    Wu, L.
    Cang, S.
    Zhao, J.
    Li, X.
    Peng, L.
    Fan, Z.
    Shen, G.
    Zhou, Q.
    Zou, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1312 - S1312
  • [37] CLINICAL OUTCOMES AFTER FIRST-LINE EGFR-TKI FOR PATIENTS WITH NSCLC, EGFR MUTATION, AND POOR PERFORMANCE STATUS
    Nagamata, Makoto
    Okuma, Yusuke
    Sunami, Kuniko
    Hosomi, Yukio
    Okamura, Tatsuru
    ANNALS OF ONCOLOGY, 2014, 25
  • [38] Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2
    Fang, W.
    Bu, Q.
    Wang, Q.
    Zhao, W.
    Wang, L.
    Dong, X.
    Chen, P.
    Wen, Z.
    Jia, J.
    Jiang, G.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S1587 - S1588
  • [39] Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data
    Passaro, Antonio
    Pochesci, Alessia
    Spitaleri, Gianluca
    Catania, Chiara
    Noberasco, Cristina
    Del Signore, Ester
    de Marinis, Filippo
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (10) : 1283 - 1288
  • [40] SURVIVAL OUTCOMES AMONG NSCLC PATIENTS IN EUROPE RECEIVING PLATINUM-BASED THERAPIES AS FIRST-LINE TREATMENT: RESULTS FROM THE FRAME OBSERVATIONAL STUDY
    Schnabel, Philipp
    Smit, Egbert
    Castro Carpeno, Javier D.
    Lesniewski-Kmak, Krzysztof
    Aerts, Joachim
    Villatoro, Rosa
    Kraaij, Kees
    Visseren-Grul, Carla
    Nacerddine, Karim
    D'Yachkova, Yulia
    Taipale, Kaisa
    Girvan, Allicia
    Moro-Sibilot, Denis
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S404 - S405
12345